• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Isaac Paul J bought $9,207 worth of shares (6,018 units at $1.53) (SEC Form 4)

    11/24/23 1:16:26 PM ET
    $STXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $STXS alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Isaac Paul J

    (Last) (First) (Middle)
    C/O ARBITER PARTNERS CAPITAL MANAGEMENT
    LLC, 530 FIFTH AVENUE, 20TH FLOOR

    (Street)
    NEW YORK NY 10036

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Stereotaxis, Inc. [ STXS ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) X Other (specify below)
    See Remarks
    3. Date of Earliest Transaction (Month/Day/Year)
    11/21/2023
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 11/21/2023 P 6,000 A $1.53 2,725,807 I See Footnote(1)
    Common Stock 11/22/2023 P 18 A $1.5 2,725,825 I See Footnote(1)
    Common Stock 26,000 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Securities beneficially owned by Arbiter Partners Capital Management LLC ("Arbiter"). Arbiter is a registered investment adviser that manages and/or administers Arbiter Partners QP LP, an affiliated investment fund (the "Fund") as well as certain managed accounts (the "Managed Accounts"). Mr. Isaac controls Arbiter, as well as the Managed Accounts. The securities reported as beneficially owned by Mr. Isaac include the securities beneficially owned by the Fund and the Managed Accounts. Mr. Isaac, Arbiter and the Fund have filed a Statement on Schedule 13G with respect to the common stock of the Issuer. Mr. Isaac disclaims beneficial ownership of these securities for all purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein. Includes 18,531 shares of Common Stock previously transferred into certain Managed Accounts by the beneficiaries thereof from the accounts of such beneficiaries.
    Remarks:
    Ross B. Levin, the Director of Research at Arbiter, serves on the board of directors (the "Board") of the Issuer. Mr. Levin does not serve on Board pursuant to any agreement between Arbiter and the Issuer. Accordingly, this Form 4 is being filed as a matter of caution, and without conceding that Mr. Isaac, Arbiter or the Fund is an insider of the Issuer for purposes of Section 16 of the Securities Exchange Act of 1934, as amended.
    /s/ Paul J. Isaac 11/24/2023
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $STXS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $STXS

    DatePrice TargetRatingAnalyst
    1/10/2024$5.00Buy
    ROTH MKM
    7/12/2022$6.00Buy
    Aegis Capital
    6/23/2022$6.00Buy
    B. Riley Securities
    1/5/2022$11.00Buy
    Craig-Hallum
    1/5/2022$13.00Buy
    Loop Capital
    More analyst ratings

    $STXS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • ROTH MKM initiated coverage on Stereotaxis with a new price target

      ROTH MKM initiated coverage of Stereotaxis with a rating of Buy and set a new price target of $5.00

      1/10/24 8:16:33 AM ET
      $STXS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Aegis Capital initiated coverage on Stereotaxis with a new price target

      Aegis Capital initiated coverage of Stereotaxis with a rating of Buy and set a new price target of $6.00

      7/12/22 9:20:32 AM ET
      $STXS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • B. Riley Securities initiated coverage on Stereotaxis with a new price target

      B. Riley Securities initiated coverage of Stereotaxis with a rating of Buy and set a new price target of $6.00

      6/23/22 8:13:15 AM ET
      $STXS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $STXS
    Financials

    Live finance-specific insights

    See more
    • Stereotaxis Reports 2025 First Quarter Financial Results

      ST. LOUIS, May 12, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the first quarter ended March 31, 2025. "We've started the year with solid execution on key commercial and innovation efforts," said David Fischel, Chairman and CEO. "This is a milestone rich year in which we are beginning to demonstrate the tangible reality and commercial impact of our comprehensive innovation strategy." "Key commercial advances include recurring revenue growth, initial commercialization of MAGiC in Europe, successful demonstrations of GenesisX as a rapidly

      5/12/25 4:01:00 PM ET
      $STXS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Stereotaxis to Report First Quarter 2025 Financial Results on May 12, 2025

      ST. LOUIS, April 22, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2025 first quarter on Monday, May 12, 2025 at the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. EST that day to discuss the Company's results and corporate developments. What:Stereotaxis first quarter 2025 financial results conference call  When:Monday, May 12, 2025, at 4:30 p.m. ET (1:30 p.m. PT)  Dial In Number:To access the live call, dial 800-715-9871 (US and Canada) or 1-646-307-1963 (International) a

      4/22/25 7:00:00 AM ET
      $STXS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Stereotaxis Reports 2024 Full Year Financial Results

      ST. LOUIS, March 03, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the fourth quarter and full year ended December 31, 2024. "We have started a milestone rich year in which we will demonstrate the tangible reality of our overall strategic transformation into a company with an easily adopted robot that can navigate a proprietary set of catheters in EP and broadly across endovascular procedures," said David Fischel, Chairman and CEO. "Our progress leads to an expanded clinical impact, scalable capital model, strategic self-sufficiency, and an attractiv

      3/3/25 7:30:00 AM ET
      $STXS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $STXS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Stereotaxis Reports 2025 First Quarter Financial Results

      ST. LOUIS, May 12, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the first quarter ended March 31, 2025. "We've started the year with solid execution on key commercial and innovation efforts," said David Fischel, Chairman and CEO. "This is a milestone rich year in which we are beginning to demonstrate the tangible reality and commercial impact of our comprehensive innovation strategy." "Key commercial advances include recurring revenue growth, initial commercialization of MAGiC in Europe, successful demonstrations of GenesisX as a rapidly

      5/12/25 4:01:00 PM ET
      $STXS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Stereotaxis to Report First Quarter 2025 Financial Results on May 12, 2025

      ST. LOUIS, April 22, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2025 first quarter on Monday, May 12, 2025 at the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. EST that day to discuss the Company's results and corporate developments. What:Stereotaxis first quarter 2025 financial results conference call  When:Monday, May 12, 2025, at 4:30 p.m. ET (1:30 p.m. PT)  Dial In Number:To access the live call, dial 800-715-9871 (US and Canada) or 1-646-307-1963 (International) a

      4/22/25 7:00:00 AM ET
      $STXS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Stereotaxis to Feature First-Ever Live Demo of GenesisX Robotic System at HRS 2025

      ST. LOUIS, April 21, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, announced today it will host a live demonstration of the GenesisX Robotic System at this year's Heart Rhythm Symposium (HRS), taking place April 24 – 27 in San Diego, CA. This marks the first live, public demonstration of GenesisX, offering a glimpse to HRS attendees into the robot's revolutionary clinical capabilities and "weekend" installation. GenesisX represents the latest advance in endovascular surgical robotics, building upon the proven benefits of Robotic Magnetic Navigation while significantly enhancing accessibi

      4/21/25 8:00:00 AM ET
      $STXS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $STXS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Financial Officer Peery Kimberly R.

      4 - Stereotaxis, Inc. (0001289340) (Issuer)

      4/10/25 4:05:06 PM ET
      $STXS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Director Isaac Paul J bought $68,780 worth of shares (38,000 units at $1.81), increasing direct ownership by 77% to 87,299 units (SEC Form 4)

      4 - Stereotaxis, Inc. (0001289340) (Issuer)

      3/11/25 3:38:02 PM ET
      $STXS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Director Isaac Paul J bought $44,836 worth of shares (24,788 units at $1.81), increasing direct ownership by 90% to 49,066 units (SEC Form 4)

      4 - Stereotaxis, Inc. (0001289340) (Issuer)

      3/10/25 10:32:20 AM ET
      $STXS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $STXS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $STXS
    SEC Filings

    See more

    $STXS
    Leadership Updates

    Live Leadership Updates

    See more
    • Director Isaac Paul J bought $68,780 worth of shares (38,000 units at $1.81), increasing direct ownership by 77% to 87,299 units (SEC Form 4)

      4 - Stereotaxis, Inc. (0001289340) (Issuer)

      3/11/25 3:38:02 PM ET
      $STXS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Director Isaac Paul J bought $44,836 worth of shares (24,788 units at $1.81), increasing direct ownership by 90% to 49,066 units (SEC Form 4)

      4 - Stereotaxis, Inc. (0001289340) (Issuer)

      3/10/25 10:32:20 AM ET
      $STXS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Director Isaac Paul J bought $15,350 worth of shares (8,095 units at $1.90) (SEC Form 4)

      4 - Stereotaxis, Inc. (0001289340) (Issuer)

      8/20/24 8:38:24 PM ET
      $STXS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Stereotaxis Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Stereotaxis, Inc. (0001289340) (Filer)

      5/19/25 12:13:29 PM ET
      $STXS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 10-Q filed by Stereotaxis Inc.

      10-Q - Stereotaxis, Inc. (0001289340) (Filer)

      5/13/25 4:00:14 PM ET
      $STXS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Stereotaxis Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

      8-K - Stereotaxis, Inc. (0001289340) (Filer)

      5/12/25 4:05:18 PM ET
      $STXS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Stereotaxis Technology to be Featured at Annual Meeting of the Society for Cardiac Robotic Navigation

      ST. LOUIS, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will participate in the Society for Cardiac Robotic Navigation's Annual Meeting taking place October 28-29 in Lisbon, Portugal. The global physician-led Society for Cardiac Robotic Navigation (SCRN) is dedicated to establishing a community and platform for users of robotic technologies in cardiology. The annual SCRN conference provides a venue for physicians and healthcare professionals to share best practices, discuss new clinical literature, and evaluate the latest innovations in technology. The

      10/21/24 8:41:13 AM ET
      $STXS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Stereotaxis Strengthens Board of Directors with Appointment of Nachum Shamir

      ST. LOUIS, July 18, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, today announced the appointment of Nachum "Homi" Shamir to its Board of Directors. Mr. Shamir most recently served as Chairman and Chief Executive Officer of Luminex Corporation from 2014 through its sale to DiaSorin S.p.A. for $1.8 Billion in 2021. Prior to Luminex, Mr. Shamir served as President and Chief Executive Officer of Given Imaging from 2006 through its sale to Covidien for $1 Billion in 2014. He currently serves as Chairman of Mediwound, a publicly-traded leader in enzymatic therapeutics for burn and wound-care, and SSI Diagnosti

      7/18/24 4:13:00 PM ET
      $STXS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Stereotaxis Strengthens Board of Directors with Appointment of Myriam J. Curet, M.D.

      ST. LOUIS, July 26, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced the appointment of Myriam J. Curet, M.D., to its Board of Directors. Dr. Curet currently serves as Executive Vice President and Chief Medical Officer for Intuitive Surgical, the global leader and pioneer of robotic surgery. Dr. Curet joined Intuitive Surgical in 2005 and has since led the development of clinical evidence, physician education, and reimbursement and regulatory activities that have been instrumental to Intuitive Surgical's growth across multiple clinical specialties. For more than 20 years, Dr. Cu

      7/26/21 9:00:00 AM ET
      $STXS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $STXS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Stereotaxis Inc. (Amendment)

      SC 13G/A - Stereotaxis, Inc. (0001289340) (Subject)

      2/14/24 4:26:22 PM ET
      $STXS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by Stereotaxis Inc. (Amendment)

      SC 13G/A - Stereotaxis, Inc. (0001289340) (Subject)

      2/14/23 4:32:50 PM ET
      $STXS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by Stereotaxis Inc. (Amendment)

      SC 13G/A - Stereotaxis, Inc. (0001289340) (Subject)

      2/14/22 5:07:16 PM ET
      $STXS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care